Table 3d.
Univariate probabilities of outcomes by disease status prior to transplant
| CR, VGPR | PR | MR, NR, Progressive | P-value | ||||
|---|---|---|---|---|---|---|---|
|
| |||||||
| Outcome event | N eval. |
Prob (95% CI)a | N eval. |
Prob (95% CI)a | N eval. |
Prob (95% CI)a | |
| ANC > 0.5 × 109/L | 41 | 20 | 28 | ||||
| @ 28 days | 85 (69-93) | 80 (55-92) | 89 (68-97) | 0.6971 | |||
| @100 days | 93 (78-98) | 100 | 89 (68-97) | ||||
| Platelets > 20 × 109 /L | 34 | 19 | 25 | ||||
| @ 60 days | 69 (50-82) | 57 (30-76) | 48 (27-66) | 0.2639 | |||
| @100 days | 72 (53-85) | 62 (35-81) | 52 (31-70) | 0.2919 | |||
| Acute GVHD, Grades 2-4 | 36 | 19 | 25 | ||||
| @100 days | 19 (9-34) | 32 (13-52) | 36 (18-55) | 0.3178 | |||
| @ 180 days | 19 (9-34) | 32 (13-52) | 40 (21-58) | 0.2031 | |||
| Chronic GVHD | 41 | 20 | 28 | ||||
| @ 1 year | 5 (1-15) | 10 (2-28) | 25 (11-42) | 0.0755 | |||
| @ 3 years | 7 (2-18) | 10 (2-28) | 25 (11-42) | 0.1634 | |||
| @5 years | 7 (2-18) | 10 (2-28) | 25 (11-42) | 0.1634 | |||
| Transplant-related mortality | 41 | 19 | 33 | ||||
| @ 100days | 15 (6-27) | 21 (7-41) | 24 (11-40) | 0.5641 | |||
| @ 1 year | 15 (6-27) | 21 (7-41) | 36 (21-52) | 0.0973 | |||
| @ 3 years | 15 (6-27) | 21 (7-41) | 36 (21-52) | 0.0973 | |||
| @ 5 years | 15 (6-27) | 21 (7-41) | 36 (21-52) | 0.0973 | |||
| Relapse | 41 | 19 | 33 | ||||
| @ 1 year | 18 (8-31) | 67 (41-84) | 48 (31-64) | <.0001 | |||
| @ 3 years | 44 (28-59) | 67 (41-84) | 55 (36-70) | 0.223 | |||
| @ 5 years | 47 (30-61) | 67 (41-84) | 61 (42-75) | 0.2627 | |||
| Disease-free survival | 41 | 19 | 33 | ||||
| @ 1 year | 67 (50-80) | 12 (2-31) | 16 (6-29) | <.0001 | |||
| @ 3 years | 41 (26-56) | 12 (2-31) | 9 (2-22) | 0.0019 | |||
| @ 5 years | 39 (24-54) | 12 (2-31) | 3 (0-13) | 0.0001 | |||
| Overall survival | 50 | 25 | 38 | ||||
| @ 1 year | 79 (65-88) | 43 (22-62) | 39 (24-55) | <.0001 | |||
| @ 3 years | 52 (37-65) | 14 (4-32) | 11 (4-24) | <.0001 | |||
| @ 5 years | 47 (32-61) | 9 (2-26) | 6 (1-16) | <.0001 | |||
Abbreviations: VGPR- Very good partial response; PR- Partial response; MR- Minimal response; NR- No response
a
Probabilities of ANC>0.5 × 109/L, Platelets > 20 × 109 /L, acute GVHD, chronic GVHD, treatment related mortality and relapse were calculated using the cumulative incidence estimate. Probabilities of overall survival and disease free survival were calculated using the Kaplan-Meier product limit estimate